CD59 glycoprotein precursor (106-114)

CD59 glycoprotein precursor (106-114) is a synthetic peptide fragment corresponding to amino acid residues 106 through 114 of the human CD59 glycoprotein precursor. As a segment of a well-characterized membrane-bound complement regulatory protein, this peptide is of significant interest in immunological and cell biology research. The defined sequence enables precise interrogation of CD59's structural and functional properties, supporting targeted studies into its biological role in inhibiting the formation of the membrane attack complex (MAC) and modulating immune responses. Its biochemical features make it a valuable tool for dissecting protein-protein interactions, epitope mapping, and the development of analytical assays focused on complement system regulation.

Epitope mapping: Researchers frequently employ the 106-114 peptide fragment for epitope mapping investigations. By using this defined sequence, scientists can identify antibody binding sites on the CD59 molecule, facilitating the characterization of monoclonal or polyclonal antibody specificity. Such mapping is essential for understanding immune recognition, developing targeted immunoassays, and designing blocking antibodies that may modulate complement activity in experimental systems.

Protein-protein interaction studies: The peptide serves as a molecular probe for elucidating the interactions between CD59 and its binding partners, particularly components of the complement cascade such as C8 and C9. Through in vitro binding assays, surface plasmon resonance, or co-immunoprecipitation experiments, the 106-114 region can be used to pinpoint critical contact sites, advancing the mechanistic understanding of how CD59 inhibits MAC assembly and protects host cells from complement-mediated lysis.

Peptide-based assay development: The defined sequence of the CD59 glycoprotein precursor (106-114) supports the design and optimization of peptide-based assays. It can function as a standard or positive control in ELISA, Western blot, or mass spectrometry workflows, enabling the quantification or detection of anti-CD59 antibodies or related analytes. Its use enhances assay specificity and reproducibility, which is crucial for high-throughput screening and immunodiagnostic research.

Structural and conformational analysis: The peptide offers a model system for investigating the structural attributes of the CD59 protein's C-terminal region. Techniques such as nuclear magnetic resonance (NMR) spectroscopy, circular dichroism (CD), or molecular dynamics simulations can utilize this fragment to study secondary structure propensity, conformational flexibility, and the impact of post-translational modifications or mutations. These insights contribute to a deeper understanding of structure-function relationships within the CD59 family.

Peptide synthesis and modification research: The 106-114 fragment is also valuable in studies focused on peptide synthesis methodologies and post-synthetic modifications. Its moderate length and sequence complexity make it a suitable candidate for evaluating novel solid-phase peptide synthesis strategies, labeling approaches, or conjugation chemistries. Such applications are relevant for researchers developing custom peptide reagents, bioconjugates, or functionalized surfaces for biosensor platforms.

1. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors

2. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

3. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

4. Myotropic activity of allatostatins in tenebrionid beetles

5. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging